Hypoxic cells in solid tumors are known to resist damage by ionizing radiation and some chemotherapeutic agents, yet hypoxic fraction is not routinely monitored in human tumors largely because methods are still inadequate or impractical. The overall aim of this proposal continues to be the development of methods to identify and quantify hypoxic cells in solid tumors. During the current funding period, a method developed in this laboratory for detection of hypoxic cells in solid tumors will be evaluated in murine and human tumors. Based on single cell microelectrophoresis, the 'comet' assay is used to quantify DNA strand breaks in individual cells. Radiobiologically hypoxic cells are about three times more resistant to DNA damage than aerobic cells, thus providing the basis for measuring hypoxic fraction in single cell suspensions prepared from solid tumors. There are several advantages to this approach which has been shown to quantify hypoxic fraction in SCCVII murine tumors. It is now necessary to determine the general applicability of the assay. The first Specific Aim is therefore to apply the comet assay to a panel of murine tumors chosen to exhibit a range of hypoxic fractions as well as different types of hypoxia (i.e., acute versus chronic hypoxia). Hypoxic fraction will be measured in Lewis lung, WiDr, SiHa, KHT and RIF-1 tumors growing in mice, and results compared with a standard method for determining hypoxic fraction, paired- survival curve analysis. Using the SCCVII tumor, hypoxic fraction will be measured in tumor cells versus macrophages, in cells close to versus distant from the blood supply, after high (5-15 Gy) and low (2 Gy) doses of radiation, and in proliferating versus non-proliferating tumor cells. In a second Specific Aim, hypoxic fraction in 10-20 accessible human tumors will be measured in tumor cells recovered from fine needle aspirates. Since reoxygenation rate may be more critical for successful radiotherapy than pre-treatment hypoxic fraction, a third Specific Aim is directed towards the development and application of a fluorescence image analysis method for quantifying changes in tumor perfusion at different times following exposure of SCCVII tumors to ionizing radiation. Results will be compared with oxygen consumption by tumor cubes, cell recovery, and hypoxic fraction measured using the comet assay. The comet assay will hopefully provide a practical method to assess both pre- and post-treatment hypoxic fractions in solid human tumors, and together with ongoing studies of tumor perfusion, tumor oxygen consumption and vascular density, will help to determine the role of hypoxia in the response of tumors to ionizing radiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037879-12
Application #
2089457
Study Section
Radiation Study Section (RAD)
Project Start
1984-03-01
Project End
1996-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
British Columbia Cancer Agency
Department
Type
DUNS #
209137736
City
Vancouver
State
BC
Country
Canada
Zip Code
V5 1-L3
Nordsmark, Marianne; Loncaster, Julie; Aquino-Parsons, Christina et al. (2006) The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 80:123-31
Nordsmark, Marianne; Loncaster, Juliette; Aquino-Parsons, Christina et al. (2003) Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 67:35-44
Olive, Peggy L; Banath, Judit P; Durand, Ralph E (2002) The range of oxygenation in SiHa tumor xenografts. Radiat Res 158:159-66
Olive, P L; Luo, C-M; Banath, J P (2002) Local hypoxia is produced at sites of intratumour injection. Br J Cancer 86:429-35
Olive, P L; Durand, R E; Banath, J P et al. (2001) Analysis of DNA damage in individual cells. Methods Cell Biol 64:235-49
Partridge, S E; Aquino-Parsons, C; Luo, C et al. (2001) A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys 49:575-80
Olive, P L; Banath, J P; Aquino-Parsons, C (2001) Measuring hypoxia in solid tumours--is there a gold standard? Acta Oncol 40:917-23
Olive, P L; Aquino-Parsons, C; MacPhail, S H et al. (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61:8924-9
Oloumi, A; MacPhail, S H; Johnston, P J et al. (2000) Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res 60:5747-53
Olive, P L; Durand, R E; Raleigh, J A et al. (2000) Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer 83:1525-31

Showing the most recent 10 out of 62 publications